[ASAP] Design and Preclinical Characterization Program toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders 🔗 Access full article via ACS Journal of Medicinal ChemistryShare:TwitterFacebookEmailRedditMoreLinkedInWhatsAppTelegramMastodon
